A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
A phase 1/2 trial of AP203 in non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer, run by AP Biosciences Inc., now recruiting.
Overview
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies is a phase 1/2 interventional study registered as NCT05473156 by AP Biosciences Inc., with 168 participants planned, started 2023-07-24 and due to reach its primary completion in 2026-12. Interventions recorded: AP203.
Similar pages
not linked directly; found by shared links- TrialA Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors
Shares AP Biosciences and the tag pipeline.
- TrialA Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of IDP-001 in Advanced or Metastatic Solid Tumors
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of MT-4561 in Patients With Various Advanced Solid Tumors
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of DM005 in Patients With Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.